Cambridge, MA (USA) and Brisbane (Australia) – Queensland University of Technology (QUT) in Brisbane, Australia, together with SynDevRx, Inc., a leader in polymer-drug conjugates for cancer and for metabolic  dysfunction are honored to announce the receipt of a $1.2 million grant from the US Department of Defense (DoD) for continued research on evexomostat, SynDevRx’s novel clinical drug candidate targeting late-stage, androgen receptor pathway inhibitor resistant prostate cancer. More specifically, the research grant will fund both a pilot clinical study and mechanistic research in the lethal form of late-stage prostate cancer referred to as ‘Aggressive Variant’ (AVPC), including the challenging neuroendocrine tumor phenotype. This award was based on evexomostat’s surprisingly potent pre-clinical activity in PDX prostate cancer models.EINPresswire-775270180-1-2m-grant-awarded-for-groundbreaking-prostate-cancer-research-on-syndevrx-metap2-inhibitor-evexomostat 08Jan 2025